Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0ZCBLX
ADC Name
J591-SC239C-Compound (XV)
Synonyms
J591-SC239C Compound (XV)
   Click to Show/Hide
Organization
Orum Therapeutics, Inc.
Drug Status
Investigative
Indication
In total 1 Indication(s)
Prostate cancer [ICD11:2C82]
Investigative
Drug-to-Antibody Ratio
1-2
Structure
Antibody Name
J591-SC239C
  Antibody Info 
Antigen Name
Glutamate carboxypeptidase 2 (FOLH1)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
J591-SC239C-Compound (XV) linker
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
0.24
nM
LNCaP cells
Prostate carcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.24 nM Positive PSMA expression (PSMA+++/++)
Method Description
The cells, at a predetermined concentration, were plated into 96 well plates, and, after overnight incubation at 37°C/5% CO2, serial dilutions of each test article (TA) were added to the cells. Cells were incubated with test articles for 72 hours. and viability was detected with CellTiter-Gloreagent.
In Vitro Model Prostate carcinoma LNCaP cells CVCL_0395
References
Ref 1 Linkers for use in antibody drug conjugates; 2023-03-16.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.